Stock Traders Buy Large Volume of Pyxis Oncology Put Options (NASDAQ:PYXS)

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of unusually large options trading on Thursday. Stock investors bought 4,270 put options on the company. This represents an increase of 614% compared to the average daily volume of 598 put options.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on PYXS shares. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They set a “buy” rating and a $9.00 price target for the company. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Zacks Research cut shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Stephens raised their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pyxis Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Hedge Funds Weigh In On Pyxis Oncology

Several large investors have recently made changes to their positions in PYXS. Bank of America Corp DE raised its holdings in shares of Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares in the last quarter. Longaeva Partners L.P. bought a new stake in Pyxis Oncology during the third quarter worth approximately $1,117,000. Citadel Advisors LLC acquired a new position in Pyxis Oncology in the third quarter worth approximately $749,000. Jane Street Group LLC bought a new position in shares of Pyxis Oncology in the second quarter valued at $370,000. Finally, Schulhoff & Co. Inc. increased its holdings in shares of Pyxis Oncology by 125.4% in the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after buying an additional 153,000 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS traded down $1.55 during mid-day trading on Thursday, reaching $1.82. 6,282,535 shares of the company traded hands, compared to its average volume of 639,161. The firm has a market cap of $113.31 million, a PE ratio of -1.15 and a beta of 1.37. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The stock has a fifty day simple moving average of $4.10 and a 200-day simple moving average of $2.38.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. As a group, analysts predict that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.